Comparative Pharmacology
Head-to-head clinical analysis: LODINE XL versus OXAPROZIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE XL versus OXAPROZIN.
LODINE XL vs OXAPROZIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which results in anti-inflammatory, analgesic, and antipyretic effects.
400 mg or 600 mg orally once daily.
600-1200 mg orally once daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Clinical Note
moderateOxaprozin + Gatifloxacin
"Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxaprozin + Rosoxacin
"Oxaprozin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxaprozin + Levofloxacin
"Oxaprozin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxaprozin + Trovafloxacin
"Oxaprozin may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 50–60 hours in healthy adults; clinical context: once-daily dosing achieves steady-state in 7–10 days.
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Primarily hepatic metabolism (glucuronidation and hydroxylation) with renal excretion of metabolites; less than 1% excreted unchanged in urine; fecal elimination accounts for ~20%.
Category C
Category D/X
NSAID
NSAID